| Index | S&P 500 | P/E | 80.46 | EPS (ttm) | 3.55 | Insider Own | 0.15% | Shs Outstand | 1.77B | Perf Week | 0.08% |
| Market Cap | 504.76B | Forward P/E | 17.40 | EPS next Y | 16.41 | Insider Trans | -1.26% | Shs Float | 1.76B | Perf Month | 7.74% |
| Enterprise Value | 569.01B | PEG | 7.48 | EPS next Q | - | Inst Own | 71.15% | Short Float | 0.92% | Perf Quarter | 11.18% |
| Income | 6.31B | P/S | 7.84 | EPS this Y | 40.18% | Inst Trans | 0.00% | Short Ratio | 3.27 | Perf Half Y | 43.75% |
| Sales | 64.39B | P/B | - | EPS next Y | 17.80% | ROA | 4.67% | Short Interest | 16.28M | Perf YTD | 25.01% |
| Book/sh | -3.33 | P/C | 76.84 | EPS next 5Y | 10.75% | ROE | -136.50% | 52W High | 291.41 -1.98% | Perf Year | 24.91% |
| Cash/sh | 3.72 | P/FCF | 27.72 | EPS past 3/5Y | -29.03% -2.72% | ROIC | 13.46% | 52W Low | 190.74 49.75% | Perf 3Y | 91.35% |
| Dividend Est. | 6.92 (2.42%) | EV/EBITDA | 26.86 | Sales past 3/5Y | 1.75% 5.95% | Gross Margin | 71.48% | Volatility | 2.13% 2.31% | Perf 5Y | 161.26% |
| Dividend TTM | 6.92 (2.42%) | EV/Sales | 8.84 | EPS Y/Y TTM | 48.54% | Oper. Margin | 29.32% | ATR (14) | 6.44 | Perf 10Y | 367.11% |
| Dividend Ex-Date | Oct 15, 2026 | Quick Ratio | 0.69 | Sales Y/Y TTM | 14.29% | Profit Margin | 9.81% | RSI (14) | 65.15 | Recom | 2.30 |
| Dividend Gr. 3/5Y | 5.17% 6.81% | Current Ratio | 0.81 | EPS Q/Q | 22.90% | SMA20 | 3.84% | Beta | 0.19 | Target Price | 294.00 |
| Payout | 189.71% | Debt/Eq | 20.17 | Sales Q/Q | 10.16% | SMA50 | 7.33% | Rel Volume | 0.95 | Prev Close | 285.19 |
| Employees | 57,000 | LT Debt/Eq | -18.69 | Earnings | Oct 30 | SMA200 | 21.34% | Avg Volume | 4.86M | Price | 285.64 |
| IPO Date | Jan 02, 2013 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 1.24% 1.11% | Net Debt/EBITDA | 3.03 | Volume | 4,597,448 | Change | 0.16% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-23-26 | Reiterated | Goldman Sachs | Buy | $258 → $294 |
| Oct-21-26 | Reiterated | Barclays | Overweight | $300 → $325 |
| Oct-08-26 | Reiterated | Cantor Fitzgerald | Overweight | $265 → $290 |
| Oct-07-26 | Reiterated | Morgan Stanley | Overweight | $296 → $310 |
| Oct-06-26 | Reiterated | Scotiabank | Sector Outperform | $320 |
| Sep-10-26 | Reiterated | HSBC | Buy | $300 → $315 |
| Aug-20-26 | Reiterated | Piper Sandler | Overweight | $298 → $303 |
| Aug-17-26 | Reiterated | Wells Fargo | Overweight | $295 → $300 |
| Aug-13-26 | Upgrade | Wolfe Research | Peer Perform → Outperform | $127 → $300 |
| Aug-05-26 | Upgrade | Erste Group | Hold → Buy |
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 64,386 | 61,160 | 56,334 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 18,365 | 18,204 | 16,904 | — | — | — | — | — | — | |
| Gross Profit | 46,021 | 42,956 | 39,430 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 14,674 | 14,010 | 14,752 | — | — | — | — | — | — | |
| Research and Development | 9,714 | 9,096 | 12,791 | — | — | — | — | — | — | |
| Other Operating Expense | 2,754 | -241 | 2,750 | — | — | — | — | — | — | |
| Operating Income | 18,879 | 20,091 | 9,137 | — | — | — | — | — | — | |
| Interest Expense | 2,916 | 2,893 | 2,808 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -7,264 | -10,601 | -2,613 | — | — | — | — | — | — | |
| Net Income Before Taxes | 8,699 | 6,597 | 3,716 | — | — | — | — | — | — | |
| Income Taxes | 2,383 | 2,364 | -570 | — | — | — | — | — | — | |
| Consolidated Net Income | 6,314 | 4,226 | 4,278 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | 6,316 | 4,233 | 4,286 | — | — | — | — | — | — | |
| Net Income | 6,314 | 4,226 | 4,278 | — | — | — | — | — | — | |
| EPS (Recurring) | 3.55 | 2.37 | 2.40 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | 3.55 | 2.37 | 2.40 | — | — | — | — | — | — | |
| EPS (Diluted) | 3.55 | 2.37 | 2.39 | — | — | — | — | — | — | |
| EBITDA | 21,183 | 17,629 | 14,910 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 80.46 | 96.41 | 74.35 | — | — | — | — | — | — | |
| Price To Sales Ratio | 7.86 | 6.63 | 5.58 | — | — | — | — | — | — | |
| Gross Margin | 71.48 | 70.24 | 69.99 | — | — | — | — | — | — | |
| Operating Margin | 29.32 | 32.85 | 16.22 | — | — | — | — | — | — | |
| Net Margin | 9.81 | 6.91 | 7.59 | — | — | — | — | — | — | |
| Shares Outstanding | 1,771 | 1,774 | 1,769 | — | — | — | — | — | — | |
| Market Capitalization | 505,868 | 405,341 | 314,351 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Aug 14 '26 | Sale | 250.00 | 32,710 | 8,177,500 | 74,430 | Aug 18 |
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Aug 14 '26 | Option Exercise | 79.02 | 32,710 | 2,584,744 | 107,140 | Aug 18 |
| Purdue David Ryan | SVP, Controller | Mar 04 '26 | Sale | 233.56 | 5,230 | 1,221,519 | 2,654 | Mar 06 |
| Siatis Perry C | EVP, GC AND SECRETARY | Mar 02 '26 | Sale | 234.39 | 18,668 | 4,375,549 | 4,619 | Mar 03 |
| Siatis Perry C | EVP, GC AND SECRETARY | Feb 25 '26 | Sale | 230.00 | 22,381 | 5,147,630 | 38,137 | Feb 27 |
| Siatis Perry C | EVP, GC AND SECRETARY | Feb 25 '26 | Option Exercise | 172.62 | 22,381 | 3,863,458 | 60,518 | Feb 27 |
| SALEKI-GERHARDT AZITA | EVP, CHIEF OPERATIONS OFFICER | Aug 12 '25 | Option Exercise | 54.86 | 42,370 | 2,324,418 | 219,662 | Aug 14 |
| SALEKI-GERHARDT AZITA | EVP, CHIEF OPERATIONS OFFICER | Aug 12 '25 | Sale | 198.42 | 42,370 | 8,407,055 | 177,292 | Aug 14 |
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | Aug 05 '25 | Sale | 198.51 | 13,295 | 2,639,253 | 58,247 | Aug 07 |
| Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | Mar 31 '25 | Option Exercise | 79.02 | 25,700 | 2,030,814 | 112,066 | Apr 02 |
| Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | Mar 31 '25 | Sale | 210.08 | 58,832 | 12,359,504 | 53,234 | Apr 02 |
| Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | Mar 14 '25 | Sale | 212.34 | 17,644 | 3,746,527 | 11,577 | Mar 18 |
| Siatis Perry C | EVP, GC AND SECRETARY | Mar 03 '25 | Option Exercise | 159.88 | 18,008 | 2,879,040 | 22,627 | Mar 04 |
| Siatis Perry C | EVP, GC AND SECRETARY | Mar 03 '25 | Sale | 210.00 | 18,008 | 3,781,680 | 4,619 | Mar 04 |
| RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | Mar 03 '25 | Sale | 210.45 | 21,250 | 4,472,039 | 6,130 | Mar 04 |